CLEVELAND, June 4, 2012 /PRNewswire/ -- DATATRAK International, Inc. (OTCQX: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced Ethos Clinical Group joined DATATRAK's Connect Partner Program. Ethos is a Contract Research Organization (CRO) with a focus on conducting clinical research in special populations, such as women and minorities.
"The partnership between DATATRAK and Ethos Clinical Group will allow each company to expand our scope of services and deliver best in class Data Management and Clinical Services to our clients. This partnership will further assist both companies to expand into new markets that are currently underserved by other CROs," stated Entrane Harvey, CEO of Ethos Clinical Group. "We are excited about the partnership and use of DATATRAK ONE to further our mission of helping our customers bring products to market that are safe and efficacious for Women and Minority populations."
"The partnership between Ethos and DATATRAK will open new doors for both companies as we assist Ethos in delivering its comprehensive suite of drug development services," stated Dr. Bill Gluck, VP of DATATRAK's Clinical and Consulting Services. "We are excited about the opportunity for Ethos' use of DATATRAK ONE to accelerate its mission of helping customers bring products to market in order to improve world health."
The Connect Partner Program is a collaboration between synergic companies to accelerate the drug development process. DATATRAK offers three types of partnerships: CRO, Technology and Strategic. Becoming a CRO Connect Partner provides extended service offerings to cover all areas of the drug development process concept planning to fully analyzed data and even submission reports.
About Ethos Clinical Group
Ethos Clinical Group is a niche contract research organization known for its ability to recruit and conduct clinical research in women and minority populations. The Company's foundation is based on strong ethics when delivering a quality driven approach for conducting clinical development programs of the highest integrity. Biopharmaceutical companies look to Ethos for a complete range of customized Phase I - Phase IV services, and its specialized recruitment process fosters better retention of minority patients in clinical trials. For more information, please see http://www.ethosus.com.
DATATRAK International is a worldwide technology and services company delivering eClinical solutions and related services for the clinical trials industry. DATATRAK built its multi-component, comprehensive solution on a single, unified platform and expanded this concept to include services delivery via DATATRAK's Clinical and Consulting Services group. The Company delivers a complete portfolio of software products designed to accelerate the reporting of clinical research data from sites to sponsors and ultimately regulatory authorities, faster and more efficiently than loosely integrated technologies. The DATATRAK ONE software solution, deployed worldwide through an ASP or Enterprise Transfer offering, supports Phase I - Phase IV drug and devices studies in multiple languages throughout the world. DATATRAK has offices located in Cleveland, Ohio; Bryan, Texas; and Cary (RTP), North Carolina. For more information, visit http://www.datatrak.net.
Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors which are difficult to predict and, in many instances, are beyond the control of the Company, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. For a list of certain of the factors that may cause actual results to differ materially from those contemplated in these forward looking statements, please see the Company's report filed with the OTCQX Market on May 10, 2012 announcing its results for the three-month period ending March 31, 2012. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.
SOURCE DATATRAK International, Inc.